Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.66 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14880718 | 0.89 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14880326 | 0.87 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL15040806 | 0.86 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14880713 | 0.81 | PIK3CD (0.82) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14880483 | 0.81 | HPGD (0.54) | NPC1HPGD | |
| SCHEMBL14883896 | 0.80 | PIK3CD (0.84) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14883855 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL14883865 | 0.79 | PIK3CD (0.82) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182718 | 0.79 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL182805 | 0.79 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-2790705-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | Novartis AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249139-A1 | Quinazoline Derivatives | NOVARTIS AG (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2768813-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | Novartis AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013057711-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249139-A1 | Quinazoline Derivatives | XDH, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3CA 2/4885PIK3CB 18/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.